Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Menarini Stories

2014-02-04 16:27:53

DUBLIN, Feb. 4, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/5wg9cc/hemoglobin_a1c) has announced the addition of the "Concise Analysis of the International Hemoglobin A1c Testing Markets" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Hemoglobin A1c (HbA1c) testing is the most recent major technology to have entered the diabetes testing market. As the global prevalence of diabetes mellitus continues to increase...

2014-02-03 16:24:44

DUBLIN, February 3, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/msw982/highgrowth ) have announced the addition of the "High-Growth Diagnostic Testing Markets" [http://www.researchandmarkets.com/research/msw982/highgrowth ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along...

2013-12-09 08:27:47

OXFORD, England and BERLIN CHEMIE/MENARINI, Germany, December 9, 2013 /PRNewswire/ -- Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical development candidate under the companies' strategic oncology collaboration. The companies have initiated formal regulatory enabling studies to support an application for a clinical phase I trial in AML...

2013-12-02 08:28:15

DUBLIN, December 2, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kllnxp/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Monitoring - Global Strategic Business Report" [http://www.researchandmarkets.com/research/kllnxp/hemoglobin_a1c ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report analyzes the worldwide markets for Hemoglobin...

2013-11-21 12:28:01

DUBLIN, Ireland, November 21, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/98bhmb/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" [http://www.researchandmarkets.com/research/98bhmb/diabetes ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) There has been a dramatic increase in the incidence of diabetes worldwide, which has been...

2013-11-20 12:28:14

DUBLIN, November 20, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/hx86bd/overthecounter) has announced the addition of the "Over-the-Counter Diagnostic Products World Markets" [http://www.researchandmarkets.com/research/hx86bd/overthecounter ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The purpose of this analysis is to describe the specific market segments of the...

2013-05-27 08:21:05

ESPOO, Finland, May 27, 2013 /PRNewswire/ -- Mendor, the Finnish diabetes technology company, is proud to announce its partnership with A. Menarini Diagnostics S.r.l, one of Europe's leading diagnostics companies in the field of diabetes. The agreement will bring Mendor's all-in-one blood glucose monitoring system to nine new European markets in the first stage as a part of Menarini's established GlucoMen product family for glucose testing. A. Menarini...

2012-12-18 04:20:49

ESPOO, Finland, December 18, 2012 /PRNewswire/ -- Mendor, the Finnish diabetes technology company, continues rapid growth and is happy to announce yet another international partnership. Mendor has signed a distribution agreement with the Swedish affiliate of a major pharmaceutical company, A.Menarini Diagnostics. A. Menarini Diagnostics Sverige will continue the work Mendor started earlier in 2012 in Sweden, in the Vastra Gotaland Region, to make the all-in-one glucose meter...

2012-10-29 11:25:44

OXFORD, England and FLORENCE, Italy, October 29, 2012 /PRNewswire/ -- Menarini and Oxford BioTherapeutics (OBT) today announce a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer. The agreement covers five of OBT's antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via a different novel oncology target. The deal brings together OBT's discovery expertise with...

2009-05-11 08:59:00

Menarini Group chooses Enterprise Quality Management Solution to manage quality and maintain regulatory compliance HOLMDEL, N.J., May 11 /PRNewswire/ -- Sparta Systems, Inc., the maker of TrackWise(R) software and the market leader in enterprise quality and compliance management, today announced that Menarini Group, the world's leading Italian pharmaceutical group, has selected its TrackWise Enterprise Quality Management System (EQMS) to simplify quality processes throughout distributed...